Cartesian Therapeutics, Inc. Deferred Revenue Recognized
Cartesian Therapeutics, Inc. (RNAC) reported Deferred Revenue Recognized of -$5.85 million for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2024-11-07
- Cartesian Therapeutics, Inc. contract with customer, liability, revenue recognized for the quarter ending 2024-03-31 was -$5.44M.
- Cartesian Therapeutics, Inc. contract with customer, liability, revenue recognized for the quarter ending 2023-03-31 was -$1.34M, a 104.99% decline year-over-year.
- Cartesian Therapeutics, Inc. contract with customer, liability, revenue recognized for the quarter ending 2022-03-31 was $26.89M, a 884.98% increase year-over-year.
- Cartesian Therapeutics, Inc. contract with customer, liability, revenue recognized for the quarter ending 2021-03-31 was $2.73M, a 11275.00% increase year-over-year.
- Cartesian Therapeutics, Inc. contract with customer, liability, revenue recognized for fiscal 2021 was $51.50M, a 430.01% increase from fiscal 2020.
- Cartesian Therapeutics, Inc. contract with customer, liability, revenue recognized for fiscal 2020 was $9.72M, a 10.37% increase from fiscal 2019.
- Cartesian Therapeutics, Inc. contract with customer, liability, revenue recognized for fiscal 2019 was $8.80M, a 695.21% increase from fiscal 2018.
- Cartesian Therapeutics, Inc. contract with customer, liability, revenue recognized for fiscal 2018 was $1.11M.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 6 month | Contract with Customer, Liability, Revenue Recognized 9 month | Contract with Customer, Liability, Revenue Recognized 12 month |
|---|---|---|---|---|
| 2024-09-30 | -$5.85M 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | -$5.85M 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | -$5.44M 10-Q · filed 2024-05-08 | |||
| 2023-09-30 | -$2.97M 10-Q · filed 2023-11-13 | |||
| 2023-06-30 | -$2.00M 10-Q · filed 2023-08-17 | |||
| 2023-03-31 | -$1.34M 10-Q · filed 2023-05-04 | |||
| 2022-09-30 | -$72.04M 10-Q · filed 2022-11-03 | |||
| 2022-06-30 | $58.21M 10-Q · filed 2022-08-08 | |||
| 2022-03-31 | $26.89M 10-Q · filed 2022-05-05 | |||
| 2021-12-31 | $51.50M 10-K · filed 2022-03-10 | |||
| 2021-09-30 | $31.42M 10-Q · filed 2021-11-09 | |||
| 2021-06-30 | $14.04M 10-Q · filed 2021-08-12 | |||
| 2021-03-31 | $2.73M 10-Q · filed 2021-05-13 | |||
| 2020-12-31 | $9.72M 10-K · filed 2021-03-12 | |||
| 2020-09-30 | $4.67M 10-Q · filed 2020-11-05 | |||
| 2020-06-30 | $14.00K 10-Q · filed 2020-08-06 | |||
| 2020-03-31 | $24.00K 10-Q · filed 2020-05-07 | |||
| 2019-12-31 | $8.80M 10-K · filed 2020-03-12 | |||
| 2019-09-30 | $2.15M 10-Q · filed 2019-11-08 | |||
| 2019-06-30 | $1.83M 10-Q · filed 2019-08-08 | |||
| 2019-03-31 | $503.00K 10-Q · filed 2019-05-09 | |||
| 2018-12-31 | $1.11M 10-K · filed 2019-03-15 | |||
| 2018-09-30 | $197.00K 10-Q · filed 2018-11-08 | |||
| 2018-06-30 | $193.00K 10-Q · filed 2018-08-08 | |||
| 2018-03-31 | $0.00 10-Q · filed 2018-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |